HLA-G immunoreactivity in primary CLs.

(A) FCCL (patient BL2, original magnification [OM] × 100). (B) FCCL (patient BL1, OM × 160). (C) MZBCL (patient BL5, OM × 100). (D) Large cell CD30⁻, CD8+, TIA-1⁺ CTCL (patient TL17, OM × 200). (E) GSS (patient TL135., OM × 100). (F) A giant multinucleated HLA-G⁺ cell in GSS (OM × 200). (G) Double immunostaining for HLA-G (red) and CD79a (blue-purple) in FCCL (patient BL4, OM × 630). (H) Double immunolabeling of HLA-G (red) and CD3 (blue-purple) in FCCL (patient BL4, OM × 630). (I) HLA-G (red) and CD3 (blue-purple) immunoreactivity in CTCL (patient TL135., OM × 630). (J) Expression of HLA-G (red) and IL-10 (blue-purple) in CTCL, MF (patient TL13, OM × 200). Colocalization of HLA-G/IL-10 creates a mixed violet-purple pigment, as shown also in panel K (patient TL17, OM × 400). (L) Double immunostaining of HLA-G (red) and CD1a (blue-purple) in CTCL (patient TL4, OM × 400).